- For insulin-naïve patients in type I DM:
- Start 1/3 of total daily insulin requirement and remaining on short-acting, pre-meal insulin
- Usual initial dose range: 0.2-0.4 units/kg
- Optimal glucose lowering effect may take 5 days to fully manifest and the first insulin glargine dose may be insufficient to cover metabolic needs in the first 24 hours of use
- For insulin-naïve patients in type II DM:
- SC 0.2 units/kg/dose OD up to 10 units/day
Injection/Pre-filled syringe: 100 IU/mL
- Inject SC OD into the abdominal area, thigh or deltoid at the same time each day
- Rotate injection sites within the same region from 1 injection to the next to reduce the risk of lipodystrophy
Long-acting insulin
It stimulates peripheral glucose uptake, inhibits hepatic glucose production, inhibits lipolysis and proteolysis regulating glucose metabolism
- Hypoglycemia
- Injection site reaction
- Injection site lipodystrophy
- Myalgia
- Pruritus
- Rash
- URI
- Weight gain
- Headache
- Peripheral edema
- Hypersensitivity reaction
- Influenza
- Hypersensitivity to components
- IV use
- Hypoglycemia
- Pramlintide
Drug Status
| Availability | Prescription only |
| Pregnancy | Category B; Can be used |
| Breastfeeding | Can be used |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Basalog | 100 IU/mL | Injection | 3ml, 5mL | Biocon | Synermed Pharma |
| Lantus | 100 IU/mL | Injection (vial) | 10mL | Sanofi-Aventis | Ressourcethica Kenya |
| Lantus | 100 IU/mL | Injection (cartridge) | 3mL | Sanofi-Aventis | Ressourcethica Kenya |
| Lantus Solostar | 100 IU/mL | Pre-Filled Syringe | 5*3mL | Sanofi-Aventis | Ressourcethica Kenya |